UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No.    )*

CYTODYN, INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

23283M101

(CUSIP Number)

Carole Wright

UTEK Corporation

2109 E. Palm Avenue

Tampa, FL 33605

813-754-4330

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

January 30, 2007

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-l(e), 240.13d-l(f) or 240.13d-l(g), check the following box.  ¨

SEC 1746 (3-06)

 

 

 

 

Page 1 of 7

---

CUSIP No. 981454101
1.		Names of Reporting Persons   UTEK CORPORATION I.R.S. Identification Nos. of above persons (entities only) 59-3603677
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a)  ¨        (b)  ¨
3.		SEC Use Only
4.		Source of Funds (See Instructions)       OO
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)						¨
6.		Citizenship or Place of Organization:       Delaware
Number of Shares Beneficially Owned by Each Reporting Person With				7.		Sole Voting Power       3,897,143*
				8.		Shared Voting Power
				9.		Sole Dispositive Power       3,897,143*
				10.		Shared Dispositive Power
11.		Aggregate Amount Beneficially Owned by Each Reporting Person       3,897,143
12.		Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)						¨
13.		Percent of Class Represented by Amount in Row (11)       29.7%
14.		Type of Reporting Person (See Instructions)       CO

 

*

As of January 30, 2007 UTEK was the record owner of 2,040,000 shares of common stock of Cytodyn, Inc. and was the record owner of 100,000 shares of Series A convertible preferred stock of Cytodyn, Inc. that would be convertible after January 30, 2008 into approximately 1,857,143 shares of Cytodyn, Inc. common stock, assuming that the average of the closing prices for the Cytodyn, Inc. common stock for the 10 trading days prior to the conversion of the stock was $.70 per share, which was the market price of the common stock on January 30, 2007. All of such shares of common stock (3,897,143 shares) would constitute approximately 29.7% of the 13,124,407 shares of common stock that would be outstanding after the conversion of such convertible preferred stock (based on the number of shares outstanding as contained in the most recently available filings with the Commission by , Inc.). UTEK has the sole power to vote and dispose of all of such shares.

 

Page 2 of 7

---

CUSIP No. 981454101

 

Item 1.

Security and Issuer

The class of equity security to which this statement relates is the common stock, par value $.0001 per share (the “Common Stock”), of Cytodyn, Inc., a Colorado corporation (“Cytodyn”). The address of the principal executive offices of Cytodyn is 227 E. Palace Avenue, Suite M, Santa Fe, New Mexico 87501

 

Item 2.

Identity and Background

This statement on Schedule 13D (this “Statement”) is being filed by UTEK Corporation, a Delaware corporation (“UTEK”). UTEK is a publicly-held specialty finance company focused on technology transfers. UTEK’s services enable companies to acquire innovative technologies from universities and research laboratories worldwide. UTEK facilitates the identification and acquisition of external technologies for clients in exchange for their equity securities. In addition, UTEK offers companies the tools to search, analyze and manage university intellectual properties. UTEK is a business development company with operations in the United States and the United Kingdom. UTEK’s principal business office is located at 2109 E. Palm Avenue, Tampa, Florida 33605.

To the best of UTEK’s knowledge as of the date hereof, set forth in Schedule I to this Schedule 13D and incorporated herein by reference is the following information with respect to each director and executive officer of UTEK:

(1) name;

(2) business address;

(3) present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted; and

(4) citizenship.

During the last five years, neither UTEK nor, to the best of UTEK’s knowledge, any of its directors or executive officers has been (1) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (2) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding has been or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to federal or state securities laws or finding any violation with respect to such laws.

 

Item 3.

Source and Amount of Funds or Other Consideration

On April 6, 2006 UTEK entered into a Strategic Alliance Agreement with Cytodyn, Inc. pursuant to which UTEK agreed to perform certain services for Cytodyn during the subsequent 12-month period, relating to the identification and acquisition of new technology, in consideration of a payment of 40,000 shares of the common stock of Cytodyn. Such shares are delivered in advance and earned ratably over the 12-month period.

 

Page 3 of 7

---

CUSIP No. 981454101

 

On July 18, 2006, UTEK received 2,000,000 shares of common stock of Cytodyn in connection with the sale of its wholly-owned subsidiary, Advanced Influenza Technologies, Inc. (“AIT”), to Cytodyn. At the time of the sale, AGT held $675,000 in cash and a technology licensed from the University of Massachusetts.

On January 30, 2007, UTEK received 100,000 shares of Series A convertible preferred stock of Cytodyn Cytodyn in connection with the sale of its wholly-owned subsidiary, Advanced Genetic Technologies, Inc. (“AGT”), to Cytodyn. At the time of the sale, AGT held $100,000 in cash and a technology licensed from the CBR Institute for Biomedical Research. The 100,000 shares of Series A preferred stock are convertible into $1,300,000 worth of common shares of Cytodyn at the option of UTEK at any time after January 30, 2008, with such stock being valued based on the average of the closing prices for the Cytodyn common stock for the 10 trading days prior to the conversion of the stock.

 

Item 4.

Purpose of Transaction

UTEK has no present plans or proposals relating to Cytodyn which relate to or would result in:

 

(a)	The acquisition by any person of additional securities of Cytodyn;

 

(b)	An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving Cytodyn or any of its subsidiaries;

 

(c)	A sale or transfer of a material amount of assets of Cytodyn or any of its subsidiaries;

 

(d)	Any change in the present board of directors or management of Cytodyn, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

 

(e)	Any material change in the present capitalization or dividend policy of Cytodyn;

 

(f)

Any other material change in Cytodyn’ business or corporate structure including but not limited to, if Cytodyn is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by section 13 of the Investment Company Act of 1940;

 

(g)	Changes in Cytodyn’ charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of Cytodyn by any person;

 

(h)	Causing a class of securities of Cytodyn to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

 

(i)	A class of equity securities of Cytodyn becoming eligible for termination of registration pursuant to Section 12(g)(4)of the Act; or

 

(j)	Any action similar to any of those enumerated above.

UTEK intends to sell the shares of common stock it presently holds, and those into which it converts the preferred stock of Cytodyn in the future, as permitted under SEC Rule 144 and as market conditions permit.

 

Page 4 of 7

---

CUSIP No. 981454101

 

Item 5.

Interest in Securities of Cytodyn

As of January 30, 2007 UTEK was the record owner of 2,040,000 shares of common stock of Cytodyn, Inc. and was the record owner of 100,000 shares of Series A convertible preferred stock of Cytodyn, Inc. that would be convertible after January 30, 2008 into approximately 1,857,143 shares of Cytodyn, Inc. common stock, assuming that the average of the closing prices for the Cytodyn, Inc. common stock for the 10 trading days prior to the conversion of the stock was $.70 per share, which was the market price of the common stock on January 30, 2007.

All of such shares of common stock (3,897,143 shares) would constitute approximately 29.7% of the 13,124,407 shares of common stock that would be outstanding after the conversion of such convertible preferred stock (based on the number of shares outstanding as contained in the most recently available filings with the Commission by, Inc.). UTEK has the sole power to vote and dispose of all of such shares.

 

Item 6.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of Cytodyn

Except as described above, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 and between such persons and any person with respect to any securities of Cytodyn, including but not limited to transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

 

Item 7.

Material to Be Filed as Exhibits

 

7.1		Agreement and Plan of Acquisition, dated July 18, 2006 among Advanced Influenza Technologies, Inc., UTEK Corporation and Cytodyn, Inc.
7.2		Agreement and Plan of Acquisition, dated January 30, 2007 among Advanced Genetic Technologies, Inc., UTEK Corporation and Cytodyn, Inc.

 

Page 5 of 7

---

CUSIP No. 981454101

 

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

December 4, 2009

/S/    CAROLE R. WRIGHT

Signature

CAROLE R. WRIGHT, CFO

Name/Title

 

Page 6 of 7

---

CUSIP No. 981454101

 

Schedule I

 

NAME		WORK ADDRESS		OCCUPATION		CITIZENSHIP
Mark Berset		Comegys Insurance One Beach Drive SE Suite 230 St Petersburg, FL 33731		CEO of Comegys Insurance		US
Kwabena Gyimah-Brempong		USF – Economics Dept. 4202 E. Fowler Avenue, BSN3403 Tampa, FL 33620		Chairman & Professor of Economics USF School of Business		US
Holly Callen Hamilton		Callen & Associates Financial Assoc. 7903 Wyoming Court Minneapolis, MN 55438		President, Callen & Associates Financial Services, Inc.		US
Rt. Hon. Francis Maude		25 Victoria Street London, SW1H 0DL United Kingdom		Member of Parliament and Chairman of the Conservative Party		United Kingdom
John J. Micek III, J.D.		300 Hamilton Avenue, 4th Floor Palo Alto, CA 94301		Managing Director, Silicon Prairie Partners, LP		US
Sam I. Reiber, J.D.		2109 E. Palm Avenue Tampa, FL 33605		Attorney at Law (VP and General Counsel for UTEK)		US
Doug Schaedler		2109 E. Palm Avenue Tampa, FL 33605		President UTEK Corporation		US
Keith A. Witter, J.D.		423 3rd Avenue SE Rochester, MN 55904		President, FFP Investment Advisors, Inc.		US

 

Page 7 of 7